Taken together, these results demonstrate that NSLC01 is active against clinically relevant pancreatic cancer cell lines and ex vivo-cultured tumor tissues, with cytotoxic effects based on NRF2/NQO1 activation. The gene discussed is NQO1; the disease is pancreatic neoplasm.